{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Rodriguez-Mora S"],"funding":["Instituto de Salud Carlos III","NIH grant","Spanish Ministry of Science and Innovation","Coordinated Research Activities at the National Center of Microbiology"],"pagination":["2344"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10137176"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["15(8)"],"pubmed_abstract":["The high morbimortality due to SARS-CoV-2 infection in oncohematological diseases (OHD) and hematopoietic stem cell transplant (HSCT) recipients in the pre-vaccine era has made vaccination a priority in this group. After HSCT, the immune responses against common vaccines such as tetanus, varicella, rubella, and polio may be lost. However, the loss of immunity developed by COVID-19 vaccination after HSCT has not been completely defined. In this study, both humoral and cellular immunity against SARS-CoV-2 were analyzed in 29 individuals with OHD who were vaccinated before receiving allogeneic (<i>n</i> = 11) or autologous (n = 18) HSCT. All participants had low but protective levels of neutralizing IgGs against SARS-CoV-2 after HSCT despite B-cell lymphopenia and immaturity. Although antibod"],"journal":["Cancers"],"pubmed_title":["Persistent Immunity against SARS-CoV-2 in Individuals with Oncohematological Diseases Who Underwent Autologous or Allogeneic Stem Cell Transplantation after Vaccination."],"pmcid":["PMC10137176"],"funding_grant_id":["R01AI143567","PID2019-110275RB-I00","PI21/00877; PI22CIII/00059","COV20_00679"],"pubmed_authors":["Perez-Olmeda M","Murciano-Anton MA","Torres M","Mateos E","Perez-Lamas L","Casado-Fernandez G","Alcami J","Garcia-Perez J","Garcia-Gutierrez V","Sainero MS","Corona M","Lopez-Jimenez J","Rodriguez-Mora S","Coiras M","Sanchez-Menendez C"],"additional_accession":[]},"is_claimable":false,"name":"Persistent Immunity against SARS-CoV-2 in Individuals with Oncohematological Diseases Who Underwent Autologous or Allogeneic Stem Cell Transplantation after Vaccination.","description":"The high morbimortality due to SARS-CoV-2 infection in oncohematological diseases (OHD) and hematopoietic stem cell transplant (HSCT) recipients in the pre-vaccine era has made vaccination a priority in this group. After HSCT, the immune responses against common vaccines such as tetanus, varicella, rubella, and polio may be lost. However, the loss of immunity developed by COVID-19 vaccination after HSCT has not been completely defined. In this study, both humoral and cellular immunity against SARS-CoV-2 were analyzed in 29 individuals with OHD who were vaccinated before receiving allogeneic (<i>n</i> = 11) or autologous (n = 18) HSCT. All participants had low but protective levels of neutralizing IgGs against SARS-CoV-2 after HSCT despite B-cell lymphopenia and immaturity. Although antibod","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Apr","modification":"2025-04-22T05:15:50.549Z","creation":"2025-04-05T21:14:32.384Z"},"accession":"S-EPMC10137176","cross_references":{"pubmed":["37190272"],"doi":["10.3390/cancers15082344"]}}